PT - JOURNAL ARTICLE AU - Zhou, Quan AU - van den Berg, Nynke S. AU - Kang, Wenying AU - Pei, Jacqueline AU - Nishio, Naoki AU - van Keulen, Stan AU - Engelen, Myrthe A. AU - Lee, Yu-Jin AU - Hom, Marisa AU - Vega Leonel, Johana C. M. AU - Hart, Zachary AU - Vogel, Hannes AU - Cayrol, Romain AU - Martin, Brock A. AU - Roesner, Mark AU - Shields, Glenn AU - Lui, Natalie AU - Gephart, Melanie Hayden AU - Raymundo, Roan C. AU - Yi, Grace AU - Granucci, Monica AU - Grant, Gerald A. AU - Li, Gordon AU - Rosenthal, Eben L. TI - Applications of fluorescence-guided surgery across multiple tumor types using a near-infrared labeled EGFR antibody AID - 10.1101/2021.10.15.21265068 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.15.21265068 4099 - http://medrxiv.org/content/early/2021/10/18/2021.10.15.21265068.short 4100 - http://medrxiv.org/content/early/2021/10/18/2021.10.15.21265068.full AB - Background As receptor-ligand based strategies emerge for surgical imaging, the relative importance of receptor expression in different tumor types is unknown. Near-infrared (NIR) labeled epidermal growth factor receptor (EGFR) antibody, panitumumab-IRDye800, was evaluated across three cancers to demonstrate its clinical utilities and a holistic analysis framework.Methods Thirty-one patients diagnosed with high-grade glioma (HGG, n=5, NCT03510208), head and neck squamous cell carcinoma (HNSCC, n=23, NCT02415881) or lung adenocarcinoma (LAC, n=3, NCT03582124) received systemic administration of 50 mg panitumumab-IRDye800 days prior to surgery. Intraoperative NIR laparoscopic or open-field images of the surgical field were acquired and tissue mimicking phantoms were constructed to identify optimal imaging conditions. Margin distance was correlated to fluorescence on resected specimen surface. Panitumumab-IRDye800 distribution was registered to histology in fixed tissue sections. Immunohistochemistry characterized EGFR expression.Results Intraoperative NIR imaging enhanced tumor contrast against surrounding healthy tissue by 5.2-fold, 3.4-fold and 1.4-fold in HGG, HNSCC and LAC, respectively. Imaging quality was optimal at the lowest gain possible under ambient light. Ex vivo NIR fluorescence identified 78 – 97% of at-risk resection margins, with 72 – 92% sensitivity and 67 – 96% specificity for tumor in fixed tissue sections. Intratumoral panitumumab-IRDye800 concentration correlated with total tumoral EGFR expression (HGG > HNSCC > LAC) and delivery barrier. Cellular EGFR expression (80%) and tumor cell density (3000 cells/mm2) was highest in HGG.Conclusions In multiple tumor types, EGFR-targeting in fluorescence-guided surgery translated to enhanced macroscopic tumor contrast and successful margin assessment despite disparate tumor cell density and heterogeneous delivery of pantimumab-IRDye800.Translational relevance As receptor-ligand based strategies emerge for surgical imaging, the relative importance of receptor expression in different tumor types remains unexamined. Near-infrared labeled epidermal growth factor receptor (EGFR) antibody was evaluated across three cancers to demonstrate its clinical utilities and a holistic analysis framework. Targeted fluorescence imaging was performed in patients infused with a consistent dose of panitumumab-IRDye800 using the same fluorescence imaging devices. In high-grade glioma, head and neck squamous cell carcinoma and lung adenocarcinoma, EGFR-targeting in fluorescence-guided surgery translated to enhanced macroscopic tumor contrast and successful margin assessment. While total EGFR expression and delivery barrier corresponded to overall panitumumab-IRDye800 distribution in tissue, tumor depth and operating room lighting can have greater influence over the intraoperative fluorescence contrast at specific tissue surface locations of a certain patient. These factors can facilitate selecting appropriate molecular target and tumor qualities to streamline translation across institutions and regulatory approval of new imaging probes.Competing Interest StatementE.L.R. acts as consultant for LI-COR Biosciences Inc. and has equipment loans from this company. All other authors declare no conflict of interest. Clinical TrialNCT03510208, NCT02415881 and NCT03582124Funding StatementThis work was supported in part by the Stanford Comprehensive Cancer Center, the Stanford University School of Medicine Medical Scholars Program, the Netherlands Organization for Scientific Research (Rubicon; 019.171LW.022), the National Institutes of Health and the National Cancer Institute (R01CA190306), National Institute on Deafness and Other Communication Disorders (T32DC015209)， a scientific research grant from the Yokoyama Foundation for Clinical Pharmacology (YRY-1702), and an institutional equipment loan from LI-COR Biosciences Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Stanford University Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.